+0.3 ± 1.3, P < 0.001), and a significant increase in quantitative insulin sensitivity check index (+0.02 ± 0.03 vs. +7.2 ± 4.8 pmol/L, P < 0.001), homeostatic model of assessment for insulin resistance (−1.0 ± 1.1 vs. After the 6-week intervention, compared with the placebo, magnesium–zinc–calcium–vitamin D co-supplementation resulted in significant reductions in fasting plasma glucose (−0.37 ± 0.09 vs. Fasting blood samples were taken at baseline and week 6 to quantify related markers. Sixty patients with GDM, aged 18–40 years, were randomized into 2 groups to intake either magnesium–zinc–calcium–vitamin D co-supplements or placebo ( n = 30 each group) for 6 weeks in a randomized, double-blind, placebo-controlled trial. The purpose of this study was to establish the effects of magnesium–zinc–calcium–vitamin D co-supplementation on glycemic control and markers of cardiometabolic risk of GDM patients. To the best our knowledge, data on the effects of magnesium–zinc–calcium–vitamin D co-supplementation on glycemic control and markers of cardiometabolic risk in gestational diabetes mellitus (GDM) are scarce.
0 Comments
Leave a Reply. |